Abstract:
Purpose:Bulky non-small cell lung cancer (NSCLC) is difficult to achieve effective local control by conventionally fractionated radiotherapy (CRT). The present work aims to evaluate the safety and efficacy of partial stereotactic ablative boost radiotherapy (P-SABR) in bulky NSCLC. Patients and methods:From December 2012 through August 2017, 30 patients with bulky NSCLC treated with P-SABR technique were analyzed. The P-SABR plan consisted of one partial SABR plan (5-9 Gy/f, 3-6 fractions) to gross tumor boost (GTVb), followed by one CRT plan to the planning target volume (PTV). GTVb was the max volume receiving SABR to guarantee the dose of organs-at-risks (OARs) falloff to about 3 Gy/f. The total dose of PTV margin was planned to above 60 Gy. The simply CRT plans were created using the same planning parameters as the original plan, with the goal to achieve comparable OARs doses and PTV margin dose to the P-SABR plan. Dosimetric variables were acquired in both P-SABR and compared CRT plans. Toxicity, local control, and survival were also evaluated. Results:Median follow-up in survivors was 10.3 months (range=2.3-39.4 months). Eleven patients (36.7%) had partial response (PR) and ten patients (33.3%) had stable disease (SD). Two-year overall survival was 55.6%. Two-year local control rate was 85.7%. No severe acute side effects >CTCAE Grade III were observed. Compared to the simply CRT plan, P-SABR plans achieved similar doses to the OARs and Dmin, but increased dose at the isocenter, Dmean, Dmax, and biological equivalent dose (BED) significantly (P<0.05). BED in the tumor center could reach 107.3 Gy (93.2-132 Gy). Patients with B90≥65% achieved a higher local control rate than those with B90<65% (P=0.010). Conclusion:This retrospective study suggests that P-SABR is feasible and well tolerated in bulky NSCLC. Local control rate is encouraging, especially for the B90≥65% group, which may due to the ability of P-SABR to optimize BED with equivalent toxicity.
journal_name
Onco Targets Therjournal_title
OncoTargets and therapyauthors
Bai Y,Gao XS,Qin SB,Chen JY,Su MM,Liu Q,Qin XB,Ma MW,Zhao B,Gu XB,Xie M,Cui M,Qi X,Li XYdoi
10.2147/OTT.S159538subject
Has Abstractpub_date
2018-05-08 00:00:00pages
2571-2579issn
1178-6930pii
ott-11-2571journal_volume
11pub_type
杂志文章abstract:Background:Emerging researches have demonstrated that aberrantly expressed long non-coding RNAs (lncRNAs) have great significance in non-small cell lung cancer (NSCLC) progression. The aim of this study was to explore the role of lncRNA AZIN1 antisense RNA 1 (AZIN1-AS1) in NSCLC and the related mechanism. Methods:Expr...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S261497
更新日期:2020-10-09 00:00:00
abstract::Metastatic colorectal cancer (mCRC) is a highly heterogeneous disease. Its treatment outcome has been significantly improved over the last decade with the incorporation of biological targeted therapies, including anti-EGFR antibodies, cetuximab and panitumumab, and VEGF inhibitors, bevacizumab, ramucirumab, and aflibe...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S79145
更新日期:2015-10-15 00:00:00
abstract:BACKGROUND:Forkhead box Q1 (FOXQ1, also known as HFH1), a member of the forkhead transcription factor family, has been demonstrated to be overexpressed in multiple tumors and is thought to be an indicator of poor clinical outcomes. METHODS:A meta-analysis using qualified relevant literature was performed to evaluate t...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S130905
更新日期:2017-03-23 00:00:00
abstract:Purpose:Hepatocellular carcinoma (HCC) has a high incidence in China and exploring effective ways for early diagnosis is an important method to improve the prognosis of patients with HCC. Additional studies reported that. Some kinds of microRNA (miRNA) in plasma will change accordingly during HCC progress, and this cha...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S232453
更新日期:2020-03-09 00:00:00
abstract::Armillaria mellea is a honey mushroom often used in the traditional Chinese medicine "Tianma". Currently, this medicinal mushroom is also used as a dietary supplement in numerous Western and Eastern countries. Armillarikin was isolated from A. mellea, and we previously discovered that it induced cytotoxicity in human ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S103940
更新日期:2016-08-01 00:00:00
abstract:Background:Papillary thyroid cancer (PTC) is a common endocrine malignancy with relatively good prognosis. Radioactive iodine (RAI) is considered effective for patients with total or nearly total thyroidectomy, but the beneficial effects of RAI are still controversial. Materials and methods:To determine whether RAI th...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S160752
更新日期:2018-06-19 00:00:00
abstract:PURPOSE:To investigate the biological effect of gyromagnetic fields (GMFs) on cell proliferation and apoptosis of human prostatic adenocarcinoma cells and explore the underlying mechanisms. METHODS:PC-3 cells were grouped into normal control (NC) and GMF treatment groups. Cell proliferation was analyzed with kit-8 and...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S95306
更新日期:2015-11-24 00:00:00
abstract:Purpose:The aim was to investigate resveratrol effects on A549 cells proliferation. Methods:A total of 104 lung adenocarcinoma tissues and nontumor tissues were collected. BEAS-2B cells were cultured in RPMI 1640 medium (group A). A549 cells were treated with RPMI 1640 medium containing different resveratrol concentra...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S157613
更新日期:2018-05-22 00:00:00
abstract:BACKGROUND:Met and HER-2 are proto-oncogenes encoding receptor tyrosine kinase c-Met and HER-2, respectively. Hepatocyte growth factor (HGF) is a ligand of c-Met. The frequency of c-Met, HGF, and HER-2 expressions in gastric cancer and their association with other clinicopathological factors have not been fully underst...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S107946
更新日期:2016-09-22 00:00:00
abstract:Background:Many studies have explored the prognostic value of T-cell lymphoma invasion and metastasis inducing factor 1 (Tiam1) and its association with lymphatic metastasis in malignant solid tumors, but the conclusions remain controversial. Therefore, we performed a meta-analysis to systematically assess the prognost...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S191571
更新日期:2019-07-25 00:00:00
abstract:BACKGROUND:Pancreatic cancer is one of the most aggressive and intractable malignant tumors, and most deaths from pancreatic cancer are related to metastases. It has been demonstrated in vitro that overexpression of programmed death-ligand 1 (PD-L1) correlates with a lack of phosphatase and tensin homologue (PTEN) expr...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S130481
更新日期:2017-04-12 00:00:00
abstract:Background:The oncogenic potential of special AT-rich binding protein 1 (SATB1) has been reported in various types of cancer, but its function in cervical cancer remains not fully investigated. This study aimed to investigate the effect of SATB1 mRNA expression on tumor progression and outcomes in the cervical cancer p...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S191414
更新日期:2019-01-30 00:00:00
abstract:Background:MicroRNA-647 (miR-647) has been reported to repress cell tumorigenic phenotype, while the function of miR-647 in non-small cell lung cancer was obscure. Methods:The effect of miR-647 and TRAF2 on A549 and H1299 cells was explored through Methyl thiazolyl tetrazolium (MTT) assay, colony formation and cell cy...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S159337
更新日期:2018-10-10 00:00:00
abstract:Background:The relationship of inflammation and tumor is becoming more and more important in the study on the pathogenesis of colorectal cancer. The role of TLR9-mediated immune inflammation reaction in the process is not currently clear. The purpose of the study was to discuss the correlation of TLR9 signal activation...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S174274
更新日期:2018-09-18 00:00:00
abstract:OBJECTIVES:Talimogene laherparepvec is the first oncolytic immunotherapy to receive approval in Europe, the USA and Australia. In the randomized, open-label Phase III OPTiM trial (NCT00769704), talimogene laherparepvec significantly improved durable response rate (DRR) versus granulocyte-macrophage colony-stimulating f...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S115245
更新日期:2016-11-16 00:00:00
abstract:Introduction:Melanoma has been reported as the most common malignancy in skin cancer. The small nucleolar RNA host gene 5 (SNHG5), an lncRNA, has been proven as a vital regulator in several types of carcinoma. This study was designed to investigate the detailed roles and possible mechanisms of SNHG5 in melanoma progres...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S184078
更新日期:2018-12-24 00:00:00
abstract:Background:Huaier extract has been a part of traditional Chinese medicine (TCM) for roughly 1600 years and may serve as a potential anti-cancer drug as it is associated with good efficacy and low toxicity. Individuals with inflammatory bowel disease (IBD) are at a higher chance of being diagnosed with colorectal cancer...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S253598
更新日期:2020-08-26 00:00:00
abstract:Background:Lung cancer is one of the most common malignancies in the world and is at the forefront of causes of all cancer deaths. Identification of new prognostic predictors or therapeutic targets might improve a patient's survival rate. Purpose:The Homeodomain interacting protein kinases (HIPKs) function as modulato...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S166878
更新日期:2018-10-25 00:00:00
abstract::The development of deep-sequencing methods is now unveiling a new landscape of previously undetected gene fusion across different tumor types. Chromosomal translocation involving the NTRK gene family occur across a wide range of cancers in both children and adults. Preclinical studies have demonstrated that chimeric p...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S177051
更新日期:2019-04-30 00:00:00
abstract::Historically, patients with locally advanced or metastatic melanoma have an extremely poor prognosis. In recent years, major breakthroughs in cutaneous melanoma treatment have led to remarkable improvements in patient outcomes. However, there are limited published data on the efficacy of these novel therapies in the t...
journal_title:OncoTargets and therapy
pub_type:
doi:10.2147/OTT.S177111
更新日期:2018-12-04 00:00:00
abstract::Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy that is cured in as few as 15%-40% of cases. Tremendous improvements in AML prognostication arose from a comprehensive analysis of leukemia cell genomes. Among normal karyotype AML cases, mutations in the FLT3 gene are the ones most commonly detect...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S103790
更新日期:2017-02-03 00:00:00
abstract::Background: Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer morbidity and mortality worldwide. In the present study, we identified novel biomarkers associated with the pathogenesis of NSCLC aiming to provide new diagnostic and therapeutic approaches for NSCLC. Methods: The microarray datasets of...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S198621
更新日期:2019-05-13 00:00:00
abstract:Background:Sesquiterpene lactones are plant-derived, natural, bioactive molecules often used against inflammatory diseases in traditional Chinese medicines. Recently, sesquiterpene lactones have been reported to exhibit potent anticancer activity. In the present study, we have investigated the anticancer activity of Br...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S179730
更新日期:2018-10-16 00:00:00
abstract:Purpose:Circular RNAs (circRNAs) are emerging as promising biomarkers for various human malignancies. However, the application of circRNAs as non-invasive biomarkers in high-grade serous ovarian cancer (SOC) remains to be elucidated. Here, we aim to investigate the feasibility of using serum circSETDB1, a tumor-promoti...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S220700
更新日期:2019-09-11 00:00:00
abstract::Oncolytic viruses (OVs) have the ability to selectively replicate in and lyse cancer cells. Angiogenesis is an essential requirement for tumor growth. Like OVs, the therapeutic effect of many angiogenesis inhibitors has been limited, leading to the development of more effective approaches to combine antiangiogenic the...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S46974
更新日期:2013-07-31 00:00:00
abstract:BACKGROUND:Progression-free survival (PFS) and time to progression (TTP) are frequently used to establish the clinical efficacy of anti-cancer drugs. However, the surrogacy of PFS/TTP for overall survival (OS) remains a matter of uncertainty in metastatic breast cancer (mBC). This study assessed the relationship betwee...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S63302
更新日期:2014-06-18 00:00:00
abstract::Purpose: Wolf-Hirschhorn syndrome candidate 1 (WHSC1) is an epigenetic modifier, considered to play a driving role in oncogenesis. However, very little is known about the roles of WHSC1 and its prognostic impacts in cervical cancer. This study aimed to investigate the role of WHSC1 in the prognosis of cervical cancer ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S204701
更新日期:2019-06-17 00:00:00
abstract::Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted ...
journal_title:OncoTargets and therapy
pub_type: 杂志文章,评审
doi:10.2147/OTT.S84153
更新日期:2016-07-25 00:00:00
abstract:Purpose:Programmed death ligand 1 (PD-L1) is widely used for predicting immune checkpoint inhibitors but has a limited effect on predicting clinical response. The aim of this study was to examine the prognostic value and PD-1 inhibitor therapeutic efficiency of SNX20 in lung adenocarcinoma. Methods:We evaluated the mR...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S262909
更新日期:2020-10-09 00:00:00
abstract:OBJECTIVES:This study aimed to analyze incidence and mortality trends in breast cancer (BC), corpus uteri cancer (CUC), and ovarian cancer (OC) in Poland in the context of sociodemographic changes. MATERIALS AND METHODS:Incidence and mortality data (1980-2013) were retrieved from the Polish National Cancer Registry, w...
journal_title:OncoTargets and therapy
pub_type: 杂志文章
doi:10.2147/OTT.S112187
更新日期:2016-09-07 00:00:00